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Rheumatoid Arthritis Naive T Cells Share Hypermethylation
Sites With Synoviocytes
Brooke Rhead,1 Calliope Holingue,1 Michael Cole,1 Xiaorong Shao,1 Hong L. Quach,1
Diana Quach,1 Khooshbu Shah,2 Elizabeth Sinclair,2 John Graf,2 Thomas Link,2
Ruby Harrison,2 Elior Rahmani,3 Eran Halperin,4 Wei Wang,5 Gary S. Firestein,5
Lisa F. Barcellos,1 and Lindsey A. Criswell2
Objective. To determine whether differentially
methylated CpGs in synovium-derived fibroblast-like
synoviocytes (FLS) of patients with rheumatoid arthri-
tis (RA) were also differentially methylated in RA
peripheral blood (PB) samples.
Methods. For this study, 371 genome-wide DNA
methylation profiles were measured using Illumina
HumanMethylation450 BeadChips in PB samples from
63 patients with RA and 31 unaffected control subjects,
specifically in the cell subsets of CD141 monocytes,
CD191 B cells, CD41memory T cells, and CD41 naive
T cells.
Results. Of 5,532 hypermethylated FLS candidate
CpGs, 1,056 were hypermethylated in CD41 naive T cells
from RA PB compared to control PB. In analyses of a sec-
ond set of CpG candidates based on single-nucleotide
polymorphisms from a genome-wide association study of
RA, 1 significantly hypermethylated CpG in CD41 mem-
ory T cells and 18 significant CpGs (6 hypomethylated,
12 hypermethylated) in CD41 naive T cells were found.
A prediction score based on the hypermethylated FLS
candidates had an area under the curve of 0.73 for associ-
ation with RA case status, which compared favorably to
the association of RA with the HLA–DRB1 shared epitope
risk allele and with a validated RA genetic risk score.
Conclusion. FLS-representative DNA methyla-
tion signatures derived from the PB may prove to be
valuable biomarkers for the risk of RA or for disease
status.
Rheumatoid arthritis (RA) is a chronic inflamma-
tory disease with the potential to cause substantial dis-
ability, primarily because of the erosive and deforming
process that occurs in the joints. It is the most common
systemic autoimmune disease, with a worldwide preva-
lence approaching 1% (1,2). The etiology of RA is com-
plex, with both genetic and nongenetic contributions.
Findings from a rigorous assessment of RA heritability
using twin studies suggested that 50–60% of the occur-
rence of RA in twins is explained by genetic effects (3).
Approximately 50% of this genetic contribution can be
explained by genes in the major histocompatibility com-
plex (MHC) (3). In addition, at least 101 independent
non-MHC risk loci have been identified (4). Evidence of
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a role for environmental factors has also been presented,
but currently, exposure to tobacco smoke is the only well-
established risk factor (5).
DNA methylation is an epigenetic modification
resulting from the addition of a methyl group to a cytosine
base at positions in the DNA sequence where a cytosine is
followed by a guanine (“CpGs”), which can lead to altered
expression of DNA. The process of DNA methylation is
essential for proper mammalian development and other
functions, and methylation patterns are affected by envi-
ronmental changes. Methylation status is also influenced
by the interaction between genetics and environment, and
a growing number of human diseases have been associated
with aberrant DNA methylation (6). Maintenance of
DNA methylation is critical for the development and func-
tion of immune cells (6,7).
Altered patterns of DNA methylation at CpG sites
have been observed in individuals with RA. A 1990 study
by Richardson et al found that global methylation of geno-
mic DNA from T cells of RA patients was lower when
compared to T cells of healthy controls (8). Altered meth-
ylation patterns have also been observed in small studies
of specific genes in RA, including the promoter regions of
IL6 using peripheral blood mononuclear cells (PBMCs)
and DR3 (alternative name, TNFRSF25) using synovial
fibroblasts (9,10). Liu et al studied global DNA methyla-
tion among 129 Taiwanese individuals and found that
those with RA had significantly lower levels of DNA
methylation in PBMCs compared to healthy control
PBMCs (11). Recently, Glossop et al identified ;2,000
differentially methylated CpGs in both T lymphocytes and
B lymphocytes between treatment-naive patients with
early RA and healthy individuals, and in a separate
analysis, they found that DNA methylation profiles in
synovial fluid–derived fibroblast-like synoviocytes (FLS)
had similarities with the profiles in tissue-derived FLS
(12,13).
A recent investigation identified 15,220 differen-
tially methylated CpG sites in synovium-derived FLS
between RA patients and either patients with osteoarthri-
tis or normal controls, and these differences appear to dis-
tinguish RA cases from non-RA controls (see ref. 14 and
Rhead B: personal communication). These 15,220 FLS
CpGs serve as the candidate sites for the current investiga-
tion. FLS in the synovial intimal lining of joints have key
roles in the production of cytokines that perpetuate
inflammation and in the production of proteases that con-
tribute to cartilage destruction in RA (15). An overlap in
the methylation pattern between FLS and peripheral
blood (PB) cells could be indicative of disease-associated
biologic processes detectable in the periphery. Because
samples of PB are easily accessible, such signatures may
be useful biomarkers for the risk of RA or for disease
status.
PATIENTS AND METHODS
Study design. Participants included 63 female patients
with RA (ages $18 years with a diagnosis meeting the American
College of Rheumatology 1987 revised criteria for RA [16,17])
and 31 female unaffected control subjects (locally based), all of
whom reported having European ancestry. Table 1 summarizes
the characteristics of our study population. All participants pro-
vided a PB sample for genotyping and measurement of
methylation.
Genotyping. Study participants were genotyped using
Illumina HumanOmniExpress, HumanOmniExpressExome,
or Human660W-Quad BeadChips, which were read on an
Table 1. Characteristics of the study participants at the time of blood sampling*
Patients
with RA
(n5 63)
Controls
(n5 31)
Seropositive (for RF or anti-CCP),
no. (%)
57 (90) –
Age, mean6 SD years 56.46 14.8 57.56 16.5
Smoking, no. (%)
Ever 33 (52) 13 (42)
Never 30 (48) 18 (58)
Current 4 (6) 1 (3)
Not current 59 (94) 30 (97)
Disease duration, mean6 SD years 14.06 10.5 –
Erosive disease, no. (%)
Present 39 (62) –
Absent 22 (35) –
Missing 2 (3) –
Disease activity, mean6 SD CDAI 10.16 9.2 –
* No significant differences (by Wilcoxon’s rank sum test or chi-square test) were observed between
the groups. RA5 rheumatoid arthritis; RF5 rheumatoid factor; anti-CCP5 anti–cyclic citrullinated
peptide; CDAI5Clinical Disease Activity Index (score range 0–76; data not available for 4 subjects).
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Illumina HiScan array scanner. Genotype results were merged
using Plink software, version 1.07 (18), and only single-
nucleotide polymorphisms (SNPs) that were assessed using all
3 chips were retained for analysis. SNPs with failed genotype
calls in at least 10% of individuals, those with a minor allele fre-
quency of lower than 1%, or those found to not be in Hardy-
Weinberg equilibrium (P# 0.000001) in controls were removed
from the analysis.
Ancestry. The EigenStrat program (19) was used to
visualize ancestral clustering of the study population relative to
individuals from 11 HapMap populations (20). As expected, our
study population of individuals of self-identified European
ancestry clustered with the HapMap populations of Utah
residents with ancestry from northern and western Europe and
Tuscans in Italy. We excluded individuals with self-reported
non-European ancestry, because of the potential for confound-
ing (see Supplementary Figures 1–3 for the ancestral clustering
of participants with self-identified European ancestry, available
on the Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39952/abstract).
Cell sorting. Whole blood was collected from each sub-
ject into four 10-ml EDTA collection tubes. PBMCs were iso-
lated using a Ficoll-Paque density gradient and stained with
conjugated monoclonal antibodies against CD45 (fluorescein iso-
thiocyanate conjugated), CD19 (phycoerythrin [PE] conjugated),
CD45RA (PE–Cy7 conjugated) (all from BD PharMingen),
CD3 (Brilliant Violet 421 conjugated), CD4 (CF594 conjugated)
(both from BD Horizon), CD14 (allophycocyanin [APC] conju-
gated) (BD Biosciences), and CD27 (APC–eFlour 780 conju-
gated) (ebioscience). Cells were then stored overnight in buffer
at 48C and sorted the following day, on a BD Biosciences
FACSAria fluorescence-activated cell sorter (FACS). The fol-
lowing populations were gated for sorting following exclusion of
debris and doublets: monocytes (CD451CD141), B cells
(CD451CD142CD32CD191), naive CD41 T cells (CD451
CD142CD192CD31CD41CD271CD45RA1), and memory
CD41Tcells (CD451CD142CD192CD31CD41CD45RA2).
Cell counts and purity checks were performed after sorting, and
then cells were stored frozen as a pellet at2808C.
Validation of overnight cell storage. To enable DNA
methylation profiling of a large number of FACS-sorted samples,
a protocol for storing blood samples overnight prior to sorting
was established and validated. Whole blood was collected from a
single individual into ten 10-ml EDTA collection tubes. PBMCs
were isolated and stained as described above, and then either
sorted the same day or stored overnight in buffer at 48C and
sorted the following day. Paired DNA samples from the 2 time
points were collected from all 4 cell types. All DNA samples
were quantified using a Nanodrop spectrophotometer. All sam-
ples were subjected to bisulfite conversion on the same day and
then assayed on Illumina 450k BeadChips simultaneously.
Methylation analyses. A total of 371 genome-wide
DNA methylation profiles were generated using the Illumina
Infinium HumanMethylation450 BeadChip kit and read on an
Illumina HiScan array scanner. A beta value, representing the
ratio of the fluorescence intensity of the methylated probe to the
fluorescence intensity overall (methylated plus unmethylated),
was derived for each CpG site. We performed an extensive qual-
ity control process, in which Illumina GenomeStudio software
was used to examine Jurkat cells as controls, to examine the
between-chip and within-chip variations, and to evaluate repli-
cate samples. All replicate samples had r2 values of .0.99, and
Jurkat cell replicate samples showed r2 values of .0.98. Back-
ground signal was subtracted using the methylumi R package
“noob” method (21), and the values in all samples were normal-
ized with the use of the all sample mean normalization method
(22), followed by beta-mixture quantile normalization (23) to
correct for type I and type II probe differences.
Multidimensional scaling (MDS) plots for each cell
type, before and after background subtraction and normaliza-
tion, were examined to assess for the presence of batch effects.
The batch effects were found to be minimal, and were reduced
following data normalization (for examples, see Supplemen-
tary Figures 4 and 5, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39952/
abstract). In these analyses, 286 CpG sites with low detection
rates (read P. 0.05) in more than 20% of samples were
removed, and 1 sample with low detection rates (read P. 0.05)
in more than 20% of sites was removed. The following CpG
sites were also removed from analysis: the 65 non-CpG “rs”
SNP probes included in the 450k BeadChip, the 30,969 sites
with probes predicted to hybridize to more than one location in
the genome after bisulfite conversion (cross-reactive probes),
as identified in a study by Chen et al (24), and the 28,355 sites
with a known polymorphism at the site being measured (poly-
morphic CpGs), as identified by Chen et al (24), that were
either present in our European-ancestry population or present
in Europeans in the 1,000 Genomes Project (24). The final
data set used for analysis consisted of 428,232 CpG sites in 371
samples (94 CD141 monocyte samples, 91 CD191 B cell sam-
ples, 94 CD41 memory T cell samples, and 92 CD41 naive T
cell samples).
An MDS plot of all 371 samples (Figure 1) showed
that each of the 4 immune cell types clustered together, as
expected based on their DNA methylation patterns. Differ-
ences in methylation among the different cell types were much
larger than the differences between RA patients and controls
within each cell type, as expected. There was greater scattering
for B cells, which is reflective of the diversity of that cell type,
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Figure 1. Multidimensional scaling (MDS) plot of DNA methylation
profiles in CD141 monocytes, CD191 B cells, CD41 memory T
cells, and CD41 naive T cells. This MDS plot of 371 samples (4
immune cell types each from patients with rheumatoid arthritis and
unaffected control subjects) shows that samples cluster according to
cell type, as expected.
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as compared to monocytes and the T cell subpopulations
examined in this study.
Wilcoxon’s rank sum tests. Four immune cell types
were assayed for each individual sample: CD141 monocytes,
CD191 B cells, CD41 memory T cells, and CD41 naive T cells.
Consistent with the methylation differences seen in FLS, hyper-
methylation or hypomethylation of DNA in PB samples from RA
patients relative to controls was evaluated separately for each
immune cell type. For each of the hypermethylated candidate
CpGs (n5 5,532) and hypomethylated candidate CpGs
(n5 8,406) from the FLS study, we used a 1-tailed Wilcoxon’s
rank sum test to assess differences in the median beta value
between RA patients and controls. P values were adjusted using
the Benjamini-Hochberg method, to control for the false discov-
ery rate (FDR) (25). We controlled the error rate for either 5,532
tests or 8,406 tests, depending on the candidate list. Methylation
changes at a second set of 1,788 candidate CpG sites (see Supple-
mentary Table 3, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39952/
abstract) in 98 genes deemed likely to be important to RA biology
(based on a recent genome-wide association study [GWAS]
meta-analysis of .100,000 subjects [4]) were also evaluated, and
an exploratory association analysis was conducted using all CpGs
on the 450k BeadChip. For the GWAS candidate CpGs and the
chip-wide tests, we used a 2-tailed Wilcoxon’s rank sum test, con-
trolling for 1,676 tests and 428,232 tests, respectively.
Principal components analysis (PCA). In order to
determine whether the proportions of cell subtypes in the sorted
cells were confounding the results, we performed Reference-
Free Adjustment for Cell-Type Composition (ReFACTor) anal-
ysis (26), in which a PCA is performed on a subset of sites that
are informative with respect to the cell composition in the data.
The ReFACTor method finds the most informative sites, in an
unsupervised manner. To measure the potential confounding,
we examined quantile–quantile (Q–Q) plots for each cell type
for a standard epigenome-wide association study (EWAS), using
only the methylation sites with a mean methylation level in the
range of 0.2–0.8, following the suggestion made by Liu et al to
remove consistently methylated and consistently unmethylated
probes when performing EWAS (27). Deflation was observed in
the Q–Q plots of all cell types except CD41 naive T cells, imply-
ing that power was deficient. To assess the expected Q–Q plot
under the condition of power deficiency, we permuted the
phenotype and repeated the EWAS analysis, and repeated this
procedure 100 times for each cell type.
To determine whether a correction was required in the
cell types, we used the genomic control lambda measurement of
inflation (28). We considered the median lambda of the 100
EWAS executions as the expected lambda. The approach was to
add individual ReFACTor principal components (PCs) to the
analysis until the inflation was corrected with respect to the
expected lambda (29). Only the values in the CD41 naive cells
were found to be inflated, and adjustment for the first ReFACTor
PC (PC1) resulted in removal of this inflation, suggesting that a
possible cell substructure is present in the CD41 naive cells. The
ReFACTor analysis was executed on the CD41 naive T cell data
with the parameter K5 2 (representing the number of assumed
cell types for the ReFACTOR program). We added this first
ReFACTor component, PC1, in logistic regression models to
evaluate the results that were adjusted for confounding by cell
substructure.
Logistic regression models. To evaluate possible con-
founding effects, logistic regression models of RA case status
were carried out against each FLS CpG that was significant at
q, 0.05 in the Wilcoxon’s rank sum tests (1,056 models),
adjusting for smoking, age, batch (date the plate was run), and
PC1 calculated from the ReFACTor analysis (as described
above), which aims to quantify cell substructure (26). Unadjusted
models were compared to models adjusted for age only, models
adjusted for ever having smoked only, models adjusted for batch
only, models adjusted for ReFACTor PC1 only, models adjusted
for age, smoking, and batch combined, and models adjusted for
age, smoking, batch, and ReFACTor PC1 combined.
Receiver operating characteristic (ROC) curve analyses.
ROC curve analysis was used to explore the potential for the
FLS sites to serve as a biomarker for the RA disease process, as
compared to the potential of a previously validated genetic risk
score for RA (30,31) and the presence or absence of HLA–
DRB1 shared epitope alleles (32,33). The hypermethylation
score for each person was calculated by summing the beta
Table 2. Results of candidate fibroblast-like synoviocyte CpG analyses*
Cell type
CpGs
with raw
P, 0.05
CpGs with absolute
median methylation
difference of .10%†
CpGs with absolute
median methylation
difference between
1% and 10%†
CpGs
with FDR
q, 0.05
CpGs with FDR
q, 0.05 and median
methylation
difference .1%
CD141 monocytes
Hypomethylated 263 4 175 0 0
Hypermethylated 100 0 61 0 0
CD191 B cells
Hypomethylated 96 1 59 0 0
Hypermethylated 1,408 1 732 0 0
CD41 memory T cells
Hypomethylated 262 0 204 0 0
Hypermethylated 66 1 36 0 0
CD41 naive T cells
Hypomethylated 160 1 62 0 0
Hypermethylated 2,569 0 1,105 1,056 517
* Wilcoxon’s rank sum tests were carried out for each candidate CpG in each of the 4 cell types, with 1-sided P values,
according to whether the CpG was hypermethylated or hypomethylated in the original study. FDR5 false discovery rate.
† The values for absolute median methylation differences are among the CpGs with unadjusted P, 0.05.
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values across the 1,056 significantly differentially methylated
loci in the FLS. A continuous weighted genetic risk score was
also calculated, based on the studies by Eyre et al (30) and
Yarwood et al (31). The genetic risk score included 43 of the 45
non-HLA SNPs (rs13397 and rs59466457 were missing), and it
was calculated by multiplying the number of copies of risk
alleles, using probability data from genome-wide imputation,
for each SNP by the natural logarithm of the odds ratio, as
reported in the study by Eyre et al (30), and summing these val-
ues across the 43 SNPs for each person. Presence of the shared
epitope was coded as a binary variable. Individuals with $1
copy of the following alleles were assigned a value of 1 for the
shared epitope: HLA–DRB1*0101, *0102, *0401, *0404, *0405,
*0408, or *1001 (34). The pROC package in R was used to plot
each of these variables as a predictor, with RA case status as
the response variable (35).
To determine the influence of adjusting for potential
confounders of the hypermethylation score, we created 2 addi-
tional hypermethylation scores. The first hypermethylation score
was based on the 830 FLS sites that remained significant
(P, 0.05) in the logistic regression models after adjustment for
age, smoking, and batch. The second hypermethylation score was
based on the 79 FLS sites that remained significant (P, 0.05)
after adjustment for age, smoking, batch, and ReFACTor PC1.
Study approval. Written informed consent was pro-
vided by all participants prior to inclusion in this study, and
the research was in compliance with the Declaration of Hel-
sinki. Institutional Review Board approval was estabilished in
place at the University of California, San Francisco, where the
study subjects were recruited.
RESULTS
Lack of effect of overnight cell storage. The
methylation profiles of isolated cell populations were not
impacted by overnight storage of the cells (correlation
between profiles derived from all paired samples was very
high, at r2. 0.997). Details are summarized in the Supple-
mentary Text (available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.
39952/abstract).
Identification of sites of significant hypo- or hyper-
methylation among the candidate FLS CpGs. After the P
values from Wilcoxon’s rank sum tests were adjusted for
multiple testing by controlling for the FDR (P values
adjusted for multiple testing hereafter referred to as q val-
ues), 1,056 significantly hypermethylated CpG sites in
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Figure 2. Plots of 1-sided P values and differences in median meth-
ylation levels in fibroblast-like synoviocyte CpGs between rheuma-
toid arthritis (RA) patients and unaffected controls in logistic
regression models with RA case status as the outcome and methyla-
tion beta value as the predictor variable, after adjustment for covari-
ates. CpGs in the models are those significant at q, 0.05 in
Wilcoxon’s rank sum tests. Models are adjusted for A, no covariates,
B, age only, C, smoking only, D, batch only, E, Reference-Free
Adjustment for Cell-Type Composition (ReFACTor) principal com-
ponent 1 (PC1) only, F, age, smoking, and batch together, and G,
age, smoking, batch, and ReFACTor PC1 together.
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Figure 3. Receiver operating characteristic curves of the CpG
hypermethylation score, the HLA–DRB1 shared epitope status, and
the rheumatoid arthritis (RA) genetic risk score as predictors of RA
case status. The hypermethylation score is the sum of the beta values
across the 1,056 significant CD41 naive T cell sites and is a measure
of hypermethylation. Shared epitope is a binary variable taking on
the value of 1 if a person has 1 or 2 copies of the shared epitope.
Genetic risk score is a weighted score of 43 single-nucleotide
polymorphisms, a scoring method that has been validated in previous
studies (30,31). The adjusted hypermethylation score represents the
sum of the 79 CpGs that were significant (P, 0.05) after adjustment
for age, smoking, batch, and Reference-Free Adjustment for Cell-
Type Composition principal component 1.
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CD41 naive T cells were found to have a q value of,0.05
(see Supplementary Table 1, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.39952/abstract). At this same threshold,
there were no sites of significantly hypomethylated CpG
candidates in CD41 naive T cells, nor were there any sig-
nificantly hypermethylated or hypomethylated FLS CpG
candidates in any of the remaining cell types (CD141
monocytes, CD191 B cells, and CD41 memory T cells).
Results are summarized in Table 2.
Results of logistic regression analyses. Logistic
regression analysis was conducted with RA case status as
the outcome and methylation beta value as the predictor
variable for each of the 1,056 FLS CpGs identified. Of
these, 1,035 CpGs were significantly associated with RA
case status (P, 0.05, by 1-sided test) in the unadjusted
model, while 830 CpGs remained significant when ad-
justing for age, smoking, and batch together, and 79 CpGs
remained significant when adjusting for age, smoking,
batch, and ReFACTor PC1. Results are summarized in
Supplementary Table 2 (available on the Arthritis & Rheu-
matology web site at http://onlinelibrary.wiley.com/doi/10.
1002/art.39952/abstract), and the shifts in P values with
each of the differentmodels are visualized in Figure 2.
Comparison of methylation profiles to shared
epitope status and genetic risk score as predictors of
RA risk. The association of hypermethylation of CpG
sites in CD41 naive T cells with the risk of RA was com-
pared to a weighted genetic risk score based on non-HLA
risk alleles, and also compared to the presence or absence
of the HLA–DRB1 shared epitope, a major genetic risk
factor for RA (36). The hypermethylation score and
shared epitope models each performed similarly. Figure 3
shows the ROC curves for each of the 3 measures, and
Table 3 summarizes the point estimates and 95% confi-
dence intervals (95% CIs) for the area under the ROC
curve (AUC) for association with RA case status in each
model. The hypermethylation score had the largest AUC,
at 72% (95% CI 61–83%). The shared epitope had an
AUC of 66% (95% CI 56–76%), and the genetic risk score
had an AUC of 51% (95% CI 38–63%). The AUC for the
hypermethylation score based on the 830 CpGs found to
be significant at P, 0.05 in the logistic regression model
adjusted for age, smoking, and batch was 71.8% (95% CI
61.0–82.7%), which is similar to the hypermethylation
score based on the CpGs found to be significant after
Wilcoxon’s rank sum test in unadjusted models. The AUC
using only the 79 CpGs that were significant in the logistic
regression model adjusted for age, smoking, batch, and
ReFACTor PC1 was 80.7% (95% CI 71.3–90.1%). Results
are summarized in Table 3.
Results for GWAS candidate CpGs. Among the
GWAS set of candidate CpGs assessed by Wilcoxon’s
rank sum tests (1,676 CpGs), 1 CpG (hypermethylated) in
CD41 memory cells and 18 CpGs (6 hypomethylated, 12
hypermethylated) in CD41 naive T cells were significantly
associated (q, 0.05) with RA susceptibility. Results are
summarized in Supplementary Table 4 (available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39952/abstract). We also carried
out logistic regression analysis using RA status as the out-
come for each of the 18 CpGs that were differentially
methylated in CD41 naive T cells, with adjustments for
various covariates. Results are summarized in Supplemen-
tary Table 5 (available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.
39952/abstract).
Genome-wide results. Results of the genome-
wide tests of differences in methylation are summarized in
Supplementary Table 6 (available on the Arthritis & Rheu-
matology web site at http://onlinelibrary.wiley.com/doi/10.
1002/art.39952/abstract). No CpG sites were significantly
differentially methylated after correction for multiple test-
ing (adjusting the P value for 428,232 tests). Differences in
global methylation were investigated by comparing the
mean methylation levels in RA patients to those in unaf-
fected controls (for results, see Supplementary Table 7,
available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.39952/abstract). No
significant differences in mean methylation levels were
observed in any cell type.
Table 3. ROC curve analyses of predictors of association with RA
case status*
Model AUC (95% CI)
Hypermethylation score (1,056 CpG sites) 72 (61–83)
Presence of the HLA–DRB1 shared epitope 66 (56–76)
Genetic risk score 51 (38–63)
Hypermethylation score (830 CpG sites;
regression model adjusted for age,
smoking, batch)
72 (61–83)
Hypermethylation score (79 CpG sites;
regression model adjusted for age,
smoking, batch, ReFACTor PC1)
81 (71–90)
* Analyses of the area under receiver operating characteristic
(ROC) curve (AUC), expressed as a percentage, were carried out
for a hypermethylation score based on the 1,056 CpG sites signifi-
cant at q, 0.05 from the Wilcoxon’s rank sum tests. This score was
compared to shared epitope status (positive/negative) and a rheuma-
toid arthritis (RA) genetic risk score. Two other hypermethylation
scores were constructed based on the 1,056 CpGs that remained sig-
nificant (P, 0.05) in logistic regression models after adjustment for
various covariates. 95% CI5 95% confidence interval; ReFACTor
PC15 Reference-Free Adjustment for Cell-Type Composition prin-
cipal component 1.
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DISCUSSION
In the present study, hypermethylated CpG sites
previously identified in FLS of patients with RA relative to
patients with osteoarthritis or healthy controls were also
distinguished in CD41 naive T cells from the PB of RA
patients relative to healthy controls. Our results show that
a disease-associated signature can be observed in cells
obtained from whole blood, which is more accessible than
the synovial fluid for clinical or epidemiologic studies.
The results of our study extend the recent findings
demonstrating that DNA methylation profiles in PBMCs
differ between RA patients and controls (12). While
Glossop et al observed differences in both B lymphocytes
and T lymphocytes (12), most results from the present
study were confined to CD41 naive T cells. However,
taken together, the combined findings increase the evi-
dence that PB cells contain a DNA methylation signature
that can distinguish patients with RA from unaffected con-
trols. Furthermore, the DNA methylation profile differ-
ences detected in T cells of treatment-naive patients in the
study by Glossop et al (12) suggest that there are methyla-
tion changes important in RA that are not a consequence
of medication or long disease duration.
The 1,056 differentially methylated candidate FLS
CpGs associated with RA in this study were limited to the
CD41 naive T cell population. Most of the observed dif-
ferences were small, with a difference in median beta
value of,10% between RA patients and controls. Of the
1,056 sites, 517 had a methylation difference of .1%
(results in Supplementary Table 1). These 517 sites re-
sided in 357 genes as well as intergenic regions, and
across all chromosomes. It is uncertain what effect size is
biologically meaningful for DNA methylation. Some
researchers impose a threshold of either 5% or 10% dif-
ference in methylation to consider the results relevant
(37), while others include modest effect sizes (38). One
recent study showed replicable methylation differences
associated with smoking, ranging from 1.2% to 24% (39).
Although differences in this study were small, they
were robust, surviving stringent multiple-testing correction.
A hypermethylation score constructed from the 1,056 sig-
nificant CpG sites predicted RA case status with an AUC
of 73%, and awaits validation in an independent data set.
The hypermethylation score based on the 830 CpG sites
with significance at P, 0.05 after adjustment for smoking,
age, and batch in the logistic regression models had a simi-
lar AUC, of 71.8%, suggesting that the score was not
strongly influenced by these covariates. The hyper-
methylation score calculated using the 79 CpG sites with
significance at P, 0.05 after adjustment for smoking, age,
batch, and ReFACTor PC1 in the logistic regression
models had a slightly higher AUC, of 80.7%, suggesting
that adjustment for possible cell substructure may improve
the ability of our FLS CpG site score to serve as a bio-
marker for RA. Because DNA methylation was measured
subsequent to the diagnosis of RA, we cannot determine
with certainty whether the FLS methylation signature in
the CD41 naive T cells is predictive of an RA diagnosis or
is a biomarker of the disease process.
One of the top 10 replicated sites (those with the
most significant P values) in CD41 naive T cells,
cg21480173, was found in the gene TYK2, which has been
associated with RA and other autoimmune diseases (40).
The remaining 9 top hits were found in the following
genes: PRKAR1B, ABCC4, COMT, CAI2, MCF2L,
GALNT9, C7orf50, or non-gene regions, which have not
been previously associated with RA. These results demon-
strate that novel genes related to RA may be discovered
through DNA methylation analysis. We also observed dif-
ferential methylation in CpG sites that reside in genes that
have previously been associated with RA (4). For example,
2 of the CpGs reside in the promoter regions for both
GATA3 and GATA3-AS1 (cg17566118 and cg15852223),
and both are hypomethylated in RA patients relative to
controls. It is important to note that our results were not
due to genetic variation or to genetic ancestry differences
between RA patients and controls.
The lack of significant findings in cell types other
than CD41 naive T cells suggests that CD41 naive T cells
are particularly relevant to RA through epigenetic mecha-
nisms involving DNA methylation. There is strong evi-
dence from previous studies that aberrant T cell activation
pathways are involved in the pathogenesis of RA, includ-
ing in the naive T cell population, which has not yet partic-
ipated in immune responses (41). CD41 naive T cells
from RA patients have been shown 1) to have premature
senescence, 2) to be defective in up-regulating telomerase
due to deficiencies in the telomerase component human
telomerase reverse transcriptase, 3) to have increased
DNA damage load and increased rates of apoptosis, 4) to
be unable to metabolize amounts of glucose equal to those
metabolized by healthy control cells of the same age, and
5) to generate lower amounts of ATP (42–45). Although
our methylation findings need to be replicated, the striking
findings in CD41 naive T cells and the existing literature
on abnormalities in this cell population in RA suggest that
the methylation changes observed may be involved in dis-
ease pathogenesis.
However, it is also plausible that methylation
changes are a response to the disease process itself or are
a result of exposure to medications. Additional studies
involving patients with early or preclinical disease will be
required to determine at what point in the course of the
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disease process such differential methylation patterns
occur. Longitudinal studies may also help elucidate why
results from the present study support a hypermethylation
signature in RA, in contrast to a signature of hypomethyl-
ation, which has been demonstrated in previous studies
(8,11). Hypermethylation may occur at a specific point
along the course of RA, or may be specific to the FLS-
associated sites rather than the global methylome.
Results from logistic regression modeling suggest
that although some variables are confounding the relation-
ship between methylation and RA case status, evidence
for association persists. Specifically, adjustments for age or
smoking did not markedly impact the number of FLS
CpGs that were significantly associated with RA at
P, 0.05. Adjusting for batch or ReFACTor PC1 reduced
the number of statistically significant CpGs by ;200, but
many remained statistically significant (841 in models
adjusted for batch, 837 in models adjusted for ReFACTor
PC1). Even when all 4 of these variables were controlled
for in the models, 79 CpGs remained significant. Figure 2
visually represents the shifting of the P values across these
regression models. Evidence for association also persisted
in analyses of GWA-identified candidate CpGs, even in
fully adjusted models (results in Supplementary Table 5).
This study has many strengths. DNA methylation
profiles were analyzed in 4 sorted cell types from 94 indi-
viduals, all of whom were women of European ancestry,
which reduced the genetic heterogeneity of the study pop-
ulation. Examination of individual cell types from FACS-
sorted blood allowed us to measure methylation results
with more confidence, rather than relying on whole blood
and cell type proportions (46). Restriction of the study to
female subjects eliminates the possibility of confounding
by sex. Moreover, since RA affects women at a 3:1 ratio
relative to men, results are generalizable to the group who
experience the greatest disease burden.
Stringent quality control of the methylation data,
as described in Patients and Methods, is another strength
of this study. In addition to implementation of the stan-
dard quality control steps of background subtraction, nor-
malization, and removal of sites with low quality scores,
CpG sites with known SNPs in individuals of European
ancestry at the cytosine or guanine being measured on the
450k BeadChip were removed, which is important because
methylation measurements for CpG sites harboring SNPs
are likely to simply reflect genetic polymorphism at that
site rather than a true measure of methylation. We also
removed from analysis CpG sites with cross-reactive
sequencing probes on the 450k BeadChip, i.e., probes that
could hybridize to more than one location in the genome
and reflect methylation at 2 different genomic locations
rather than only the intended target site. Rigorous quality
control measures increase confidence that the observed
differential methylation is an accurate reflection of the dis-
ease biology, and not due to artifacts.
Both whole genome and whole methylome data
were utilized in the present study. The whole genome data
allowed us to determine the genetic ancestry of all partici-
pants. The original FLS study by Whitaker et al involved
anonymous samples, and the authors did not have informa-
tion on ethnicity or race (14). Therefore, it is possible that
we are underestimating the overlap between FLS and
CD41 naiveT cell sites if we are comparing different ethnic-
ities in analyzing the CD41 naive T cell and FLS samples.
In addition, we were able to demonstrate that even after
controlling for age, smoking, batch, and possible cell sub-
structure (ReFACTor PC1), a number of FLS and GWA
candidate sites remain significantly associatedwithRA.
This study also has limitations. We could not assess
temporality between methylation and RA case status.
Results may be confounded by case-specific factors such as
medication and inflammation. Indeed, other studies have
observed associations between methylation and medi-
cations (47,48); however, the case–control nature of the
present study did not allow us to adjust for the effects of RA
medications, since they were present only amongRA cases.
Our findings are restricted to CpG sites that are
represented on the 450k BeadChip. The BeadChip priori-
tized inclusion of features such as RefSeq genes, CpG
islands, shores, and shelves, areas of the genome such as
theMHC region, and sites known to be important in cancer
(49,50). Therefore, additional CpG sites relevant to RA
may be missing. Furthermore, although our ROC analysis
demonstrated that differential methylation of ;1,000
CpGs in the PB has the potential to distinguish RA cases
from controls, our hypermethylation score needs to be fur-
ther tested as a predictor in an independent data set.
ACKNOWLEDGMENT
We thank Vladimir Chernitskiy for his assistance in
data acquisition.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it
critically for important intellectual content, and all authors approved
the final version to be published. Dr. Criswell had full access to all of
the data in the study and takes responsibility for the integrity of the
data and the accuracy of the data analysis.
Study conception and design. Shao, Link, Barcellos, Criswell.
Acquisition of data. Shao, H. L. Quach, D. Quach, Shah, Sinclair, Graf,
Link, Harrison, Wang, Firestein, Barcellos, Criswell.
Analysis and interpretation of data. Rhead, Holingue, Cole, Link,
Rahmani, Halperin, Firestein, Barcellos, Criswell.
DNA METHYLATION SIGNATURES IN RA PERIPHERAL BLOOD 557
REFERENCES
1. Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD, Tanasescu R.
Extra-articular manifestations in rheumatoid arthritis. Maedica
(Buchar) 2010;5:286–91.
2. Gabriel SE, Michaud K. Epidemiological studies in incidence,
prevalence, mortality, and comorbidity of the rheumatic diseases.
Arthritis Res Ther 2009;11:229.
3. MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J,
Aho K, et al. Characterizing the quantitative genetic contribution
to rheumatoid arthritis using data from twins. Arthritis Rheum
2000;43:30–7.
4. Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, et al.
Genetics of rheumatoid arthritis contributes to biology and drug
discovery. Nature 2014;506:376–81.
5. K€allberg H, Ding B, Padyukov L, Bengtsson C, R€onnelid J,
Klareskog L, et al. Smoking is a major preventable risk factor
for rheumatoid arthritis: estimations of risks after various expo-
sures to cigarette smoke. Ann Rheum Dis 2011;70:508–11.
6. Robertson KD. DNA methylation and human disease. Nat Rev
Genet 2005;6:597–610.
7. Ohkura N, Kitagawa Y, Sakaguchi S. Development and mainte-
nance of regulatory T cells. Immunity 2013;38:414–23.
8. Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S,
Johnson M. Evidence for impaired T cell DNA methylation in
systemic lupus erythematosus and rheumatoid arthritis. Arthritis
Rheum 1990;33:1665–73.
9. Takami N, Osawa K, Miura Y, Komai K, Taniguchi M, Shiraishi
M, et al. Hypermethylated promoter region of DR3, the death
receptor 3 gene, in rheumatoid arthritis synovial cells. Arthritis
Rheum 2006;54:779–87.
10. Nile CJ, Read RC, Akil M, Duff GW, Wilson AG. Methylation
status of a single CpG site in the IL6 promoter is related to IL6
messenger RNA levels and rheumatoid arthritis. Arthritis
Rheum 2008;58:2686–93.
11. Liu C, Fang T, Ou T, Wu C, Li R, Lin Y, et al. Global DNA
methylation, DNMT1, and MBD2 in patients with rheumatoid
arthritis. Immunol Lett 2011;135:96–9.
12. Glossop JR, Emes RD, Nixon NB, Packham JC, Fryer AA,
Mattey DL, et al. Genome-wide profiling in treatment-naive
early rheumatoid arthritis reveals DNA methylome changes in T
and B lymphocytes. Epigenomics 2016;8:209–24.
13. Glossop JR, Haworth KE, Emes RD, Nixon NB, Packham JC,
Dawes PT, et al. DNA methylation profiling of synovial fluid
FLS in rheumatoid arthritis reveals changes common with
tissue-derived FLS. Epigenomics 2015;7:539–51.
14. Whitaker JW, Shoemaker R, Boyle DL, Hillman J, Anderson D,
Wang W, et al. An imprinted rheumatoid arthritis methylome sig-
nature reflects pathogenic phenotype. GenomeMed 2013;5:40.
15. Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector
cells in rheumatoid arthritis. Immunol Rev 2010;233:233–55.
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF,
Cooper NS, et al. The American Rheumatism Association 1987
revised criteria for the classification of rheumatoid arthritis.
Arthritis Rheum 1988;31:315–24.
17. Barton JL, Trupin L, Schillinger D, Gansky SA, Tonner C, Mar-
garetten M, et al. Racial and ethnic disparities in disease activity and
function among persons with rheumatoid arthritis from university-
affiliated clinics. Arthritis Care Res (Hoboken) 2011;63:1238–46.
18. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender
D, et al. PLINK: a tool set for whole-genome association and
population-based linkage analyses. Am JHumGenet 2007;81:559–75.
19. Patterson N, Price AL, Reich D. Population structure and
eigenanalysis. PLoS Genet 2006;2:e190.
20. International HapMap Consortium. The International HapMap
Project. Nature 2003;426:789–96.
21. Davis S, Du P, Bilke S, Triche T Jr, Bootwalla M. Methylumi:
Handle Illumina methylation data. R package version 2.0. 2014.
22. Yousefi P, Huen K, Aguilar Schall R, Decker A, Elboudwarej E,
Quach H, et al. Considerations for normalization of DNA meth-
ylation data by Illumina 450K BeadChip assay in population
studies. Epigenetics 2013;8:1141–52.
23. Teschendorff AE, Marabita F, Lechner M, Bartlett T, Tegner J,
Gomez-Cabrero D, et al. A b-mixture quantile normalization
method for correcting probe design bias in Illumina Infinium
450 k DNA methylation data. Bioinformatics 2013;29:189–96.
24. Chen YA, Lemire M, Choufani S, Butcher DT, Grafodatskaya
D, Zanke BW, et al. Discovery of cross-reactive probes and poly-
morphic CpGs in the Illumina Infinium HumanMethylation450
microarray. Epigenetics 2013;8:203–9.
25. Benjamini Y, Hochberg Y. Controlling the false discovery rate:
a practical and powerful approach to multiple testing. J R Stat
Soc Ser B 1995;57:289–300.
26. Rahmani E, Zaitlen N, Baran Y, Eng C, Hu D, Galanter J,
et al. Sparse PCA corrects for cell type heterogeneity in
epigenome-wide association studies. Nat Methods 2016;13:443–5.
27. Liu Y, Aryee MJ, Padyukov L, Fallin MD, Hesselberg E,
Runarsson A, et al. Epigenome-wide association data implicate
DNA methylation as an intermediary of genetic risk in rheuma-
toid arthritis. Nat Biotechnol 2013;31:142–7.
28. Devlin B, Roeder K, Wasserman L. Genomic control, a new
approach to genetic-based association studies. Theor Popul Biol
2001;60:155–66.
29. Zou J, Lippert C, Heckerman D, Aryee M, Listgarten J. Epige-
nome-wide association studies without the need for cell-type
composition. Nat Methods 2014;11:309–11.
30. Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P, et al.
High-density genetic mapping identifies new susceptibility loci
for rheumatoid arthritis. Nat Genet 2012;44:1336–40.
31. Yarwood A, Han B, Raychaudhuri S, Bowes J, Lunt M, Pappas
DA, et al. A weighted genetic risk score using all known suscep-
tibility variants to estimate rheumatoid arthritis risk. Ann
Rheum Dis 2015;74:170–6.
32. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothe-
sis: an approach to understanding the molecular genetics of suscepti-
bility to rheumatoid arthritis. Arthritis Rheum 1987;30:1205–13.
33. Holoshitz J. The rheumatoid arthritis HLA-DRB1 shared epi-
tope. Curr Opin Rheumatol 2010;22:293–8.
34. Raychaudhuri S, Sandor C, Stahl EA, Freudenberg J, Lee HS,
Jia X, et al. Five amino acids in three HLA proteins explain
most of the association between MHC and seropositive rheuma-
toid arthritis. Nat Genet 2012;44:291–6.
35. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC,
et al. pROC: an open-source package for R and S1 to analyze and
compare ROC curves. BMC Bioinformatics 2011;12:77.
36. Van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Huizinga
TW, Toes RE, de Vries RR. The HLA–DRB1 shared epitope alleles
are primarily a risk factor for anti–cyclic citrullinated peptide anti-
bodies and are not an independent risk factor for development of
rheumatoid arthritis. Arthritis Rheum 2006;54:1117–21.
37. Stefansson OA, Moran S, Gomez A, Sayols S, Arribas-Jorba C,
Sandoval J, et al. A DNAmethylation-based definition of biologically
distinct breast cancer subtypes. Mol Oncol 2015;9:555–68.
38. Tsai PC, Bell JT. Power and sample size estimation for
epigenome-wide association scans to detect differential DNA
methylation. Int J Epidemiol 2015. E-pub ahead of print.
39. Georgiadis P, Hebels DG, Valavanis I, Liampa I, Bergdahl IA,
Johansson A, et al. Omics for prediction of environmental health
effects: blood leukocyte-based cross-omic profiling reliably predicts
diseases associated with tobacco smoking. Sci Rep 2016;6:20544.
40. Parkes M, Cortes A, van Heel DA, Brown MA. Genetic insights into
common pathways and complex relationships among immune-
mediated diseases. Nat Rev Genet 2013;14:661–73.
41. Cope AP, Schulze-Koops H, Aringer M. The central role of T
cells in rheumatoid arthritis. Clin Exp Rheumatol 2007;25 Supp
46:S4–S11.
558 RHEAD ET AL
42. Fujii H, Shao L, Colmegna I, Goronzy JJ, Weyand CM. Telome-
rase insufficiency in rheumatoid arthritis. Proc Natl Acad Sci U
S A 2009;106:4360–5.
43. Goronzy JJ, Weyand CM. Rheumatoid arthritis. Immunol Rev
2005;204:55–73.
44. Shao L, Fujii H, Colmegna I, Oishi H, Goronzy JJ, Weyand
CM. Deficiency of the DNA repair enzyme ATM in rheumatoid
arthritis. J Exp Med 2009;206:1435–49.
45. Yang Z, Fujii H, Mohan SV, Goronzy JJ, Weyand CM. Phos-
phofructokinase deficiency impairs ATP generation, autophagy,
and redox balance in rheumatoid arthritis T cells. J Exp Med
2013;210:2119–34.
46. Reinius LE, Acevedo N, Joerink M, Pershagen G, Dahlen SE,
Greco D, et al. Differential DNA methylation in purified human
blood cells: implications for cell lineage and studies on disease
susceptibility. PLoS One 2012;7:e41361.
47. Plant D, Wilson AG, Barton A. Genetic and epigenetic pre-
dictors of responsiveness to treatment in RA. Nat Rev
Rheumatol 2014;10:329–37.
48. Kim YI, Logan JW, Mason JB, Roubenoff R. DNA hypomethyl-
ation in inflammatory arthritis: reversal with methotrexate. J Lab
Clin Med 1996;128:165–72.
49. Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, Le JM, et al.
High density DNA methylation array with single CpG site reso-
lution. Genomics 2011;98:288–95.
50. Sandoval J, Heyn H, Moran S, Serra-Musach J, Pujana MA,
Bibikova M, et al. Validation of a DNA methylation microarray
for 450,000 CpG sites in the human genome. Epigenetics 2011;6:
692–702.
DOI: 10.1002/art.39999
Clinical Image: Whipple’s destructive septic arthritis
The patient, a 63-year-old woman, presented with an 8-month history of fever, weight loss (15 kg), and uveitis. Possible rheumatoid
arthritis had been diagnosed 38 years prior and was treated with prednisone and methotrexate. On examination, the patient was
found to have limited range of motion of both wrists, but no synovitis. The C-reactive protein level was elevated at 13 mg/dl, with a
decreased hemoglobin level of 7.6 gm/dl. Testing for rheumatoid factor and anti–citrullinated protein antibodies yielded negative
results. Radiologic examination showed severe bilateral erosive changes and articular cartilage loss in the radiocarpal, intercarpal,
and carpometacarpal articulations with partial ankylosis of the carpus and carpometacarpal joints. The metacarpophalangeal and
interphalangeal joints were spared. Findings of duodenojejunal biopsy with periodic acid–Schiff staining were normal. Tropheryma
whipplei was detected by polymerase chain reaction (PCR) analysis of saliva and stool specimens, and was also found in the duode-
num and cerebrospinal fluid. Whipple’s disease was diagnosed, and therapy with a combination of hydroxychloroquine, doxycycline,
and sulfadiazine was initiated, leading to rapid improvement in the clinical and laboratory findings. Whipple’s disease is often not
diagnosed until it has reached an advanced stage, due to its rarity, its broad spectrum of clinical presentations, and the existence of
forms with no clinical symptoms or histologically detectable involvement of the intestinal tract (1,2). In many instances, isolated
arthritis not affecting small joints may be the only manifestation for years. Some patients with long disease duration but no treat-
ment may develop radiologically evident destruction that does not affect the small joints and has been associated with septic arthritis
(3). PCR analysis of saliva and stool samples has become the examination of choice for diagnosis (2). Early diagnosis and treatment
are important in preventing progression of the disease.
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